

## Consolidated Results

### 1. Detailed Information from Operating Results

		rounddown under 0.1 billion yen				Forecasts			
		Mar 07	Mar 08	Change	Change	Mar 07	Mar 08	Full Year	Change
		3Q	3Q		(%)	Full Year	1H Revised	3Q Revised	(%)
Net Sales		702.5	765.2	62.6	8.9%	920.6	968.0	971.0	5.5%
Cost of Sales		226.0	226.2	0.1	0.1%	284.0			
	Ratio of Net Sales	32.2%	29.6%			30.9%			
Gross Profit		476.5	539.0	62.4	13.1%	636.5			
SG&A		326.3	293.6	-32.7	-10.0%	446.0			
	Ratio of Net Sales	46.4%	38.3%			48.4%			
Reserch and Development		123.7	92.5	-31.1	-25.2%	167.9	141.0	133.0	-20.8%
SG&A excluding R&D		202.5	201.0	-1.5	-0.8%	278.1			
Advertising and Sales Promotion		52.9	60.0	7.0	13.4%	77.4			
Salaries, Bonuses and Allowances		85.5	86.6	1.0	1.3%	117.0			
Other		64.0	54.3	-9.7	-15.2%	83.6			
Operating Income		150.2	245.3	95.1	63.4%	190.5	256.0	269.0	41.2%
	Ratio of Net Sales	21.4%	32.1%			20.7%	26.4%	27.7%	
Non Operating Income		10.9	21.2	10.3	95.1%	13.8			
Equity in earnings		1.5	8.5	6.9	449.6%	1.1			
Non Operating Expenses		4.4	6.0	1.5	35.6%	6.5			
Foreign Exchange Loss		2.7	4.6	1.8	68.1%	3.5			
Ordinary Income		156.6	260.6	103.9	66.4%	197.8	266.0	284.0	43.6%
	Ratio of Net Sales	22.3%	34.1%			21.5%	27.5%	29.2%	
Special Gain		33.3	10.8	-22.4	-67.4%	41.0			
Gain on Sale of Subsidiaries' Shares		21.2	-	-21.2	-	21.2			
Special Loss		12.2	22.0	9.8	80.0%	27.1			
Closure of Business Bases		10.9	0.9	-9.9	-	17.6			
Special Retirement Benefits		-	13.0	13.0	-	1.2			
Other		1.3	8.0	6.7	511.5%	8.2			
Income before Income Taxes		177.7	249.3	71.6	40.3%	211.7			
Income Taxes		70.0	86.5	16.4	23.5%	78.5			
Minority Interests		1.3	1.6	0.2	18.1%	1.8			
Net Income		106.3	161.2	54.9	51.7%	131.2	158.0	175.0	33.3%
	Ratio of Net Sales	15.1%	21.1%			14.3%	16.3%	18.0%	

### 2. Segment Information by Business

		billion yen				Mar 07	
		Mar 07	Mar 08	Change	Change	Full Year	
		3Q	3Q		(%)		
Sales	Consolidated	702.5	765.2	62.6	8.9%	920.6	
	Pharmaceutical	700.8	764.4	63.6	9.1%	918.5	
		Ratio of Net Sales	99.7%	99.9%			99.8%
	Other	1.7	0.8	-0.9	-53.8%	2.0	
	Ratio of Net Sales	0.3%	0.1%			0.2%	

### 3. Overseas Sales

		billion yen				Forecasts			
		Mar 07	Mar 08	Change	Change	Mar 07	Mar 08	Full Year	Change
		3Q	3Q		(%)	Full Year	1H Revised	3Q Revised	(%)
Overseas Sales		329.1	376.6	47.5	14.4%	450.0	488.1	491.2	9.1%
	Ratio of Net Sales	46.8%	49.2%			48.9%	50.4%	50.6%	
	North America	162.7	194.8	32.0	19.7%	223.2			
	Ratio of Net Sales	23.2%	25.5%			24.2%			
	Europe	134.1	146.2	12.1	9.0%	182.7			
	Ratio of Net Sales	19.1%	19.1%			19.9%			
	Asia and others	32.1	35.5	3.3	10.5%	44.0			
	Ratio of Net Sales	4.6%	4.6%			4.8%			

#### 4. Segment Information by Region

billion yen

	Mar 07 3Q	Mar 08 3Q	Change	Change (%)	Mar 07 Full Year	Mar 08 Full Year		Change (%)
						1H Revised	3Q Revised	
Sales	702.5	765.2	62.6	8.9%	920.6	968.0	971.0	5.5%
Japan	396.8	407.1	10.2	2.6%	501.6	501.4	501.9	0.0%
Ratio of Net Sales	56.5%	53.2%			54.5%	51.8%	51.7%	
North America	128.5	150.1	21.6	16.8%	173.5	201.3	198.7	14.5%
Ratio of Net Sales	18.3%	19.6%			18.9%	20.8%	20.5%	
Europe	158.4	187.2	28.8	18.2%	219.6	236.6	242.0	10.2%
Ratio of Net Sales	22.6%	24.5%			23.9%	24.4%	24.9%	
Asia	18.6	20.6	1.9	10.5%	25.7	28.7	28.4	10.5%
Ratio of Net Sales	2.7%	2.7%			2.8%	3.0%	2.9%	
Operating Income	150.2	245.3	95.1	63.4%	190.5	256.0	269.0	41.2%
Japan	97.0	155.8	58.7	60.6%	116.6			
Ratio of Net Sales	64.6%	63.5%			61.2%			
North America	40.7	50.8	10.1	24.9%	51.5			
Ratio of Net Sales	27.1%	20.7%			27.1%			
Europe	17.5	43.9	26.3	149.8%	23.7			
Ratio of Net Sales	11.7%	17.9%			12.5%			
Asia	3.2	2.5	-0.6	-19.4%	3.7			
Ratio of Net Sales	2.1%	1.1%			2.0%			
Eliminations	-8.3	-7.8	0.5		-5.2			

#### 5. Exchange Rate

yen

	Mar 07 3Q Ave	Mar 08 3Q Ave	Mar 07 3Q End	Mar 08 3Q End	Mar 07 Full Year	Mar 08 Full Year	
						1H Revised	3Q Revised
Yen/USD	116	117	119	114	117	115	114
Yen/EUR	148	163	157	167	150	159	161

\* Exchange rate fluctuation had a positive impact on net sales and operating income by 19.3 billion yen and 10.2 billion yen, respectively.

#### 6. Research and Development Expenses

billion yen

billion yen

	Mar 07 3Q	Mar 08 3Q	Change	Change (%)	Mar 07 Full Year	Mar 08 Full Year		Change (%)
						1H Revised	3Q Revised	
Research and Development	123.7	92.5	-31.1	-25.2%	167.9	141.0	133.0	-20.8%
Ratio of Net Sales	17.6%	12.1%			18.2%	14.6%	13.7%	

7.Detailed Pharmaceutical Segment Information

1)Consolidated sales of major products

	billion yen				billion yen			
	Mar 07 3Q	Mar 08 3Q	Change	Change (%)	Mar 07 Full Year	Mar 08 1H Revised	Full Year 3Q Revised	Change (%)
Prograf	129.2	154.0	24.7	19.2%	175.4	200.3	202.6	15.5%
Sales by Astellas	125.8	150.8	25.0	19.9%	170.1	195.7	198.0	16.4%
Japan	14.6	19.2	4.5	31.1%	19.0	24.0	24.0	25.9%
North America	65.7	74.8	9.0	13.7%	88.0	98.8	98.4	11.8%
Europe	38.1	48.8	10.6	27.8%	52.7	61.4	64.8	22.9%
Asia	7.1	7.9	0.8	11.4%	10.3	11.5	10.8	4.8%
Exports to third parties(Europe)	3.4	3.1	-0.2	-6.7%	5.2	4.7	4.6	-13.5%
Harnal	93.2	97.8	4.6	5.0%	127.0	121.4	123.0	-3.2%
Sales by Astellas	62.7	58.8	-3.8	-6.1%	81.4	74.1	75.7	-7.1%
Japan	30.1	30.0	-0.1	-0.4%	38.5	37.8	37.8	-2.1%
Europe	26.8	22.3	-4.4	-16.7%	35.3	27.8	29.3	-17.1%
Capsule	14.6	9.1	-5.5	-37.8%	18.8	11.2	12.2	-35.2%
Omic OCAS	12.1	13.2	1.0	8.8%	16.4	16.5	17.1	3.7%
Asia	5.7	6.1	0.4	8.1%	7.5	8.2	8.2	8.3%
Bulk and Royalties(Europe)	30.5	39.0	8.4	27.8%	45.5	47.3	47.3	3.9%
Vesicare	25.3	44.6	19.2	75.9%	36.2	61.5	60.7	67.5%
Japan	4.5	9.8	5.3	117.9%	6.2	13.8	12.8	106.2%
North America	12.0	20.8	8.7	72.5%	17.6	28.9	28.8	63.0%
Europe	8.7	13.7	5.0	57.8%	12.3	18.4	18.8	51.8%
Asia	0.0	0.1	0.1	333.1%	0.0	0.4	0.4	679.3%
Funguard/Mycamine	12.9	14.2	1.2	10.0%	16.5	17.8	17.6	6.9%
Japan	10.3	10.5	0.2	2.4%	12.8	12.7	12.7	-0.8%
North America	2.6	3.5	0.8	32.3%	3.5	4.9	4.7	31.4%
Asia	-	0.1	0.1	-	0.0	0.2	0.3	224.7%
Protopic	10.8	12.4	1.6	14.9%	14.7	17.7	16.7	13.2%
Japan	2.1	2.1	0.0	1.4%	2.6	2.8	2.8	3.9%
North America	5.2	6.0	0.8	16.4%	7.1	8.7	8.2	15.2%
Europe	3.3	3.8	0.5	17.2%	4.5	5.5	5.1	13.5%
Asia	0.2	0.3	0.0	39.4%	0.3	0.6	0.5	56.3%

- Sales of products in Japan are shown in a gross sales basis.

2) Consolidated Sales of Other Products

Rx Sales in Japan	billion yen				billion yen			
	Mar 07 3Q	Mar 08 3Q	Change	Change (%)	Mar 07 Full Year	Mar 08 1H Revised	Full Year 3Q Revised	Change (%)
Lipitor	74.5	78.2	3.7	5.1%	94.7	100.0	98.5	4.0%
Gaster	49.0	48.5	-0.5	-1.1%	62.2	60.6	60.6	-2.7%
Micardis	39.0	49.9	10.8	27.7%	50.3	62.8	62.8	24.7%
Cefzon	11.7	10.7	-1.0	-8.5%	14.7	13.0	13.0	-11.6%
Myslee	15.2	16.9	1.6	10.8%	19.4	21.7	21.7	11.8%
Vaccines	15.5	16.8	1.2	8.0%	13.3	13.4	14.8	10.6%
Seroquel	13.2	15.2	2.0	15.5%	16.8	18.7	18.7	11.0%
Frاندول	9.6	9.4	-0.2	-2.2%	12.3	12.0	12.0	-2.5%
Perdipine	6.0	5.3	-0.6	-11.2%	7.5	6.6	6.6	-12.3%
Luvox	8.8	8.9	0.1	1.3%	11.1	11.0	11.0	-1.3%
Dorner	6.1	5.8	-0.2	-4.8%	7.8	7.3	7.3	-7.0%
Dogmatyl	5.8	5.6	-0.2	-3.5%	7.3	7.1	7.1	-3.6%
Cefamezin	5.3	5.3	-0.0	-0.5%	6.6	6.4	6.4	-3.8%
Targocid	5.2	5.1	-0.1	-2.7%	6.4	6.2	6.2	-4.2%
Intal	5.1	4.4	-0.7	-13.8%	7.9	6.5	6.5	-18.7%
Nivadil	4.4	3.7	-0.7	-16.0%	5.4	4.6	4.6	-16.0%
Cibenol	4.0	4.1	0.0	2.1%	5.1	5.0	5.0	-2.4%
Nasea	3.8	3.8	0.0	0.7%	4.7	4.7	4.7	-1.8%
Starsis	3.4	3.4	0.0	0.2%	4.3	4.3	4.3	-0.9%
Celecox (Launched in June 2007)	-	2.6	2.6	-	-	3.1	3.4	-
Geninax (Launched in October 2007)	-	3.0	3.0	-	-	3.0	3.4	-
Total Rx Sales In Japan	361.4	384.2	22.8	6.3%	455.2	474.6	475.9	4.5%

- Sales of products in Japan are shown in a gross sales basis.

RX Sales in North America and EU	billion yen				billion yen			
	Mar 07 3Q	Mar 08 3Q	Change	Change (%)	Mar 07 Full Year	Mar 08 1H Revised	Full Year 3Q Revised	Change (%)
Adenoscan (North America)	27.6	29.4	1.8	6.5%	37.1	40.0	38.6	4.1%
AmBisome (North America)	6.9	6.1	-0.7	-10.4%	8.8	7.4	7.9	-10.6%
Vaprisol (North America)	0.1	0.7	0.6	588.9%	0.1	1.0	1.3	631.5%
Amevive (North America)	1.9	1.6	-0.2	-12.0%	2.4	2.8	2.1	-12.5%
Eligard (Europe)	4.1	6.8	2.6	65.1%	5.9	9.5	9.0	52.6%

Export Sales	billion yen				billion yen			
	Mar 07 3Q	Mar 08 3Q	Change	Change (%)	Mar 07 Full Year	Mar 08 1H Revised	Full Year 3Q Revised	Change (%)
Cefzon Overseas(Exports to third party)	8.9	5.1	-3.7	-42.0%	10.8	5.1	5.2	-51.9%
Cefspan Overseas(Exports to third party)	4.5	5.3	0.8	19.2%	5.7	5.7	5.7	-0.6%

Sales in Europe and North America

North America	Unit: M\$				Unit: M\$			
	Mar 07	Mar 08	Change	Change	Mar 07	Mar 08	Full Year	Change
	3Q	3Q		(%)	Full Year	1H Revised	3Q Revised	(%)
Sales	1,106	1,280	174	15.7%	1,483	1,756	1,740	17.3%
Prograf	566	637	71	12.6%	752	861	861	14.5%
Adenoscan	238	251	13	5.5%	317	349	338	6.6%
AmBisome	59	52	-6	-11.3%	75	64	69	-8.4%
Protopic	44	51	6	15.3%	60	76	72	18.1%
VESicare	104	177	73	70.9%	150	252	252	67.0%
Mycamine	22	30	7	31.1%	30	43	41	34.6%
Vaprisol	1	6	5	582.5%	1	9	9	444.5%
Amevive	16	14	-2	-12.8%	20	25	19	-10.3%

Europe	Unit: M€				Unit: M€			
	Mar 07	Mar 08	Change	Change	Mar 07	Mar 08	Full Year	Change
	3Q	3Q		(%)	Full Year	1H Revised	3Q Revised	(%)
Sales	1,070	1,150	79	7.4%	1,463	1,491	1,504	2.8%
Harnal	387	377	-10	-2.8%	538	473	476	-11.6%
Sales by Astellas	181	137	-44	-24.3%	235	175	182	-22.6%
Capsule	99	56	-43	-43.5%	126	71	76	-39.5%
OCAS	82	81	-0	-1.2%	109	104	106	-3.3%
Bulk and Royalty	206	239	33	16.1%	303	298	294	-3.1%
Prograf	281	319	38	13.6%	386	416	431	11.6%
Sales by Astellas	258	299	41	16.1%	351	387	403	14.7%
Exports to third parties	23	19	-3	-15.2%	35	29	28	-19.4%
Vesicare	58	84	25	43.4%	82	115	116	40.9%
Protopic	22	23	1	6.5%	30	35	32	5.9%
Eligard	27	41	13	50.0%	39	60	56	42.4%

Consolidated Balance Sheets

Billion yen

	30-Sep-07		31-Mar-07		Change	Comments
	Amount	Composition	Amount	Composition		
<b>Assets</b>	<b>1,477.8</b>	<b>100.0%</b>	<b>1,470.7</b>	<b>100.0%</b>	<b>7.1</b>	
<b>Current assets</b>	<b>966.1</b>	<b>65.4%</b>	<b>965.9</b>	<b>65.7%</b>	<b>0.1</b>	
Cash on hand and in banks	276.1		223.3		52.7	
Trade notes and accounts receivable	263.2		231.0		32.1	
Marketable securities	217.7		284.3		-66.5	----- Decrease in investment in CP, etc.
Inventories	87.5		90.9		-3.4	
Deferred tax assets	56.2		58.1		-1.9	
Other	66.0		78.5		-12.5	
Allowance for doubtful receivable	-0.8		-0.5		-0.3	
<b>Fixed assets</b>	<b>511.6</b>	<b>34.6%</b>	<b>504.7</b>	<b>34.3%</b>	<b>6.9</b>	
<b>Property, plant and equipment</b>	<b>188.1</b>	<b>12.7%</b>	<b>194.5</b>	<b>13.2%</b>	<b>-6.4</b>	
Buildings and structures	83.5		88.9		-5.3	
Machinery, equipment and vehicles	28.4		30.6		-2.1	
Tools, furniture and fixtures	20.1		22.3		-2.2	
Land	31.5		35.6		-4.0	
Construction in progress	24.1		16.7		7.4	
Other	0.2		0.2		0.0	
<b>Intangible fixed assets</b>	<b>79.6</b>	<b>5.4%</b>	<b>41.5</b>	<b>2.8%</b>	<b>38.0</b>	----- Goodwill associated with the acquisition of Agensys' shares
<b>Investments and other assets</b>	<b>243.9</b>	<b>16.5%</b>	<b>268.6</b>	<b>18.3%</b>	<b>-24.6</b>	
Investment securities	181.5		210.6		-29.1	
Long-term loans receivable	2.1		2.2		-0.1	
Deferred tax assets	43.8		37.1		6.7	
Other	16.5		18.6		-2.1	
Allowance for doubtful receivables	-0.2		-0.1		-0.0	

	30-Sep-07		31-Mar-07		Change	Comments
	Amount	Composition	Amount	Composition		
<b>Liabilities and Shareholders' Equity</b>	<b>1,477.8</b>	<b>100.0%</b>	<b>1,470.7</b>	<b>100.0%</b>	<b>7.1</b>	
<b>Liabilities</b>	<b>330.4</b>	<b>22.4%</b>	<b>371.7</b>	<b>25.3%</b>	<b>-41.2</b>	
<b>Current liabilities</b>	<b>273.4</b>	<b>18.5%</b>	<b>308.8</b>	<b>21.0%</b>	<b>-35.4</b>	
Trade notes and accounts payable	78.3		73.0		5.2	
Short-term loans payable	-		1.6		-1.6	
Other accounts payable	86.9		108.8		-21.9	
Accrued expenses	50.4		65.7		-15.2	
Accrued income taxes	37.2		44.3		-7.1	
Accrued consumption taxes	3.7		2.0		1.7	
Deferred tax liabilities	0.4		-		0.4	
Allowance for sales rebates and others	7.0		4.1		2.8	
Other	9.2		9.0		0.1	
<b>Long-term liabilities</b>	<b>57.0</b>	<b>3.9%</b>	<b>62.8</b>	<b>4.3%</b>	<b>-5.8</b>	
Deferred tax liabilities	0.3		0.5		-0.2	
Accrued retirement benefits for employees	18.7		18.4		0.2	
Accrued retirement benefits for directors	0.0		0.0		0.0	
Other	37.9		43.7		-5.8	
<b>Shareholders' equity</b>	<b>1,147.3</b>	<b>77.6%</b>	<b>1,098.9</b>	<b>74.7%</b>	<b>48.3</b>	
Common stock	103.0	7.0%	103.0	7.0%	0.0	
Additional paid-in capital	176.8	12.0%	176.8	12.0%	0.0	
Retained earnings	901.0	60.9%	1,006.6	68.4%	-105.6	
Treasury stock	-89.7	-6.1%	-241.9	-16.4%	152.1	- Cancellation of 45 million of treasury stock - Share buyback implemented (13.21 million shares)
Unrealized holding gain on securities	31.5	2.2%	38.0	2.6%	-6.4	
Translation adjustments	23.7	1.6%	15.7	1.1%	8.0	
Stock acquisition rights	0.5	0.0%	0.2	0.0%	0.2	
Minority interests	0.3	0.0%	0.3	0.0%	0.0	